Neurology

>

Latest News

FDA accepts sNDA for higher regimen nusinersen for spinal muscular atrophy | Image Credit: © A Illustrations raki - © A Illustrations raki - stock.adobe.com.
FDA accepts sNDA for higher regimen nusinersen for spinal muscular atrophy

January 24th 2025

The higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and higher maintenance regimen, 28 mg, every 4 months.

Study: No association between montelukast and neuropsychiatric adverse event risk | Image Credit: © iushakovsky - © iushakovsky - stock.adobe.com.
Study: No association between montelukast and neuropsychiatric adverse event risk

January 21st 2025

Using a smartphone application to screen for neonatal jaundice | Image Credit: © zilvergolf - © zilvergolf - stock.adobe.com.
Using a smartphone application to screen for neonatal jaundice

December 11th 2024

Survey: trofinetide improves tolerability among Rett syndrome patients | Image Credit: © ARBA - © ARBA - stock.adobe.com.
Survey: titrating trofinetide improves tolerability among Rett syndrome patients

December 9th 2024

Fremanezumab for episodic migraine prevention demonstrates positive phase 3 dataLatest revision | Image Credit: © Jan H. Andersen - © Jan H. Andersen - stock.adobe.com.
Fremanezumab for episodic migraine prevention demonstrates positive phase 3 data

December 4th 2024

More News

© 2025 MJH Life Sciences

All rights reserved.